Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DUBLIN, May 7, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced financial results for the first quarter ended March 31, 2013, updated 2013 financial guidance and key additions to its board of directors.
“During the first quarter, we continued to deliver strong top and bottom line growth fueled by growing sales of Xyrem and Erwinaze,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc.
Help employers find you! Check out all the jobs and post your resume.
